Tizanidine Tablet
Product Images NDC 71610-228

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 71610-228). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 4 mg (71610 0228 30)

Tizanidine 4 mg oral tablets label showing a 30 count package. The label includes storage instructions, manufacturer details listing Unichem Laboratories LTD in India, and the labeler Aphena Pharma Solutions - Tennessee, LLC in Cookeville, TN. The label also indicates the product is prescription-only.*

FDA Label Image

Molecular Structure (842f6165 899e 4f0c 98fd 0a619c84edf1 01)

Chemical structure of Tizanidine hydrochloride, showing its molecular arrangement including a chlorinated benzene ring fused with an azolopyridine structure and an imidazoline ring.*

FDA Label Image

Figure-1 (842f6165 899e 4f0c 98fd 0a619c84edf1 02)

A line graph depicting plasma tizanidine concentration (ng/mL) over time (hours) after dosing. The graph compares four groups: 2 x 4 mg tizanidine tablets with food, 2 x 4 mg tablets without food, 2 x 4 mg tizanidine capsules with food, and 2 x 4 mg capsules without food. Concentrations peak within the first few hours and decline toward zero by 24 hours post-dosing.*

FDA Label Image

Figure 3 (842f6165 899e 4f0c 98fd 0a619c84edf1 03)

A line graph depicting improvement in Ashworth score over time (hours post-dose) for 8 mg tizanidine, 16 mg tizanidine, and placebo groups. The y-axis shows the degree of improvement from -5 to 0, and the x-axis represents hours post-dose from 0 to 6. Lines indicate higher improvement with 16 mg compared to 8 mg and placebo.*

FDA Label Image

Figure 4 (842f6165 899e 4f0c 98fd 0a619c84edf1 04)

A clinical study graph showing improvement in Ashworth Score on the vertical axis over four time points: End of Titration (Study Week 3), End of Maintenance (Study Week 7), and Endpoint (Last Observation Carried Forward). The graph compares tizanidine (mean dose 28.8 mg) with placebo, illustrating greater improvement with tizanidine across all time points.*

FDA Label Image

Logo (842f6165 899e 4f0c 98fd 0a619c84edf1 05)

FDA Label Image

Aphena Pharma Solutions (TN)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.